Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
Toshihiko Doi(National Cancer Center Hospital East), Kohei Shitara(National Cancer Center Hospital East), Yoichi Naito(National Cancer Center Hospital East), Akihiko Shimomura, Yasuhiro Fujiwara, Kan Yonemori, Chikako Shimizu, Tatsunori Shimoi, Yasutoshi Kuboki(National Cancer Center Hospital East), Nobuaki Matsubara(National Cancer Center Hospital East), Atsuko Kitano, Takahiro Jikoh(Daiichi Sankyo (United States)), Caleb Lee(Daiichi Sankyo (United States)), Yoshihiko Fujisaki(Daiichi-Sankyo (Japan)), Yusuke Ogitani(Daiichi-Sankyo (Japan)), Antoine Yver(Daiichi Sankyo (United States)), Kenji Tamura
Cited by 491
Abstract
Related Papers
No related papers found
Powered by citation graph analysis